eligibility for glp-1 Medications: Everything You Need to Know Who Is Eligible for GLP-1

Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodiumglucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target

All-Day Energy & Focus

**DISCONTINUING Jan 1st 2026** GLP-1 SM 10mg lyophilized peptide for in vitro studies

I'm more active

By pairing a rapid "research flywheel" with large-scale genomic data, 23andMe Research Institute scientists identified GLP1R and GIPR variants associated with some of the variability in individual response to GLP-1 drugs, helping bridge the gap between patient experiences and precision medicine.